Pharmaceuticals

Pneumoconiosis Market Trends 2025–2029: Forecasts for Key Growth Segments

November 14, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

By How Much Is The Pneumoconiosis Market Expected To Expand Between 2025 And 2029?

The pneumoconiosis market has experienced consistent growth in recent years. It is anticipated to expand from $1.43 billion in 2024 to $1.49 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.7%. The historical expansion of this market can be attributed to the growing prevalence of occupational lung diseases, increased industrialization across emerging economies, heightened awareness about safety in the workplace, stricter government regulations concerning industrial dust exposure, and a rise in coal and silica mining activities.

The pneumoconiosis market is projected to experience consistent expansion in the coming years. This market is anticipated to reach $1.77 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 4.4%. Several factors are driving this expansion during the forecast period, including an expanding elderly demographic, wider implementation of sophisticated imaging and diagnostic tools, escalating healthcare spending, increased funding for respiratory illness research, and a rise in legal and financial claims. Key trends foreseen over this period involve progress in diagnostic imaging, the incorporation of artificial intelligence (AI) into radiology, remote monitoring solutions facilitated by technology, the evolution of wearable devices for respiratory monitoring, and enhancements in pulmonary drug delivery methods.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24661&type=smp

Which Major Market Drivers Are Shaping The Future Of The Pneumoconiosis Market?

Increased exposure to asbestos is projected to drive the expansion of the pneumoconiosis market in the future. Individuals face asbestos exposure when they breathe in or come into contact with its fibers, which can potentially lead to serious health issues such as asbestosis, mesothelioma, and lung cancer. This exposure is on the rise as the renovation and demolition of older structures release dangerous fibers into the air, thereby escalating the risks of inhalation. Breathing in asbestos fibers can result in pneumoconiosis because these fibers embed themselves in the lungs, triggering continuous inflammation. This constant irritation causes lung scarring, also known as fibrosis, which progressively hinders both breathing and general lung function. For instance, a report from July 2024 by the UK Asbestos Training Association (UKATA), a UK-based training and awareness organization, revealed that over 5,000 asbestos-related disease deaths occur annually in the UK, with 493 asbestosis-related deaths in 2022, and over 70% of these deaths are in individuals aged over 75. Consequently, the heightened exposure to asbestos is fueling the expansion of the pneumoconiosis market.

What Are The Primary Types Of Segments Analyzed In The Pneumoconiosis Market?

The pneumoconiosis market covered in this report is segmented –

1) By Type Of Pneumoconiosis: Asbestosis, Silicosis, Coal Workers’ Pneumoconiosis, Berylliosis

2) By Diagnosis: Chest X-Ray, Computed Axial Tomography Scan, Lung Function Tests, Other Diagnosis

3) By Treatment: Medication, Oxygen Therapy, Pulmonary Rehabilitation, Other Treatments

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users

Subsegments:

1) By Asbestosis: Occupational Exposure, Environmental Exposure, Secondary Exposure, Severity Level

2) By Silicosis: Chronic Silicosis, Accelerated Silicosis, Acute Silicosis, Industry Type

3) By Coal Workers’ Pneumoconiosis: Simple Coal Workers’ Pneumoconiosis (CWP), Complicated Coal Workers’ Pneumoconiosis (CWP), Underground Mining Exposure, Surface Mining Exposure

4) By Berylliosis: Acute Berylliosis, Chronic Berylliosis, Occupational Exposure, Genetic Susceptibility

What Are The Latest Industry Trends Transforming The Pneumoconiosis Market?

Leading firms in the pneumoconiosis sector are concentrating on creating sophisticated remedies, including clinical trials for medications targeting pneumoconiosis, with the goals of boosting treatment effectiveness, retarding disease advancement, and improving patient results. Such a clinical trial involves a research methodology designed to evaluate the safety, efficacy, and adverse reactions of a novel drug in treating the condition. This process enrolls human subjects and advances through various stages to ascertain the drug’s appropriateness for widespread medical application. As an illustration, in June 2022, the China-based pharmaceutical entity, Beijing Continent Pharmaceutical Co. Ltd., reported the commencement of patient enrollment for a Phase III clinical trial of Pirfenidone Capsules (F647), intended for the treatment of pneumoconiosis, a severe occupational lung ailment resulting from dust inhalation and causing fibrosis. Pirfenidone, an orally administered small-molecule drug known for inhibiting collagen synthesis and modulating fibrotic cytokines like TGF-ß, is already a significant offering for the company, and this particular trial marks its fifth therapeutic application. This Phase III investigation aims to validate the efficacy and safety of F647 for pneumoconiosis, which continues to be China’s predominant occupational disease.

Who Are The Top Performing Companies In The Pneumoconiosis Market In Recent Years?

Major companies operating in the pneumoconiosis market are AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Medtronic plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk, Koninklijke Philips NV, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals Inc., Inogen, GNI Group Ltd., DRIVE MEDICAL GMBH & CO. KG.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/pneumoconiosis-global-market-report

Which Region Currently Holds The Largest Share Of The Pneumoconiosis Market?

North America was the largest region in the pneumoconiosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumoconiosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Pneumoconiosis Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24661&type=smp

Browse Through More Reports Similar to the Global Pneumoconiosis Market 2025, By The Business Research Company

Psoriasis Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Voice Prosthesis Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/voice-prosthesis-devices-and-equipment-global-market-report

Apheresis Consumables And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/apheresis-consumables-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795